empagliflozin/linagliptin vs rifampin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of empagliflozin/linagliptin and rifampin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer.
Glyxambi
Rifadin
Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.
Rifampin is an antibiotic medicine. It fights bacteria in your body to treat infections.
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. It should be used along with diet and exercise. Glyxambi can also help lower the risk of death caused by heart problems if you have both type 2 diabetes and heart disease. It is not for people with type 1 diabetes.
Rifampin treats tuberculosis (TB) and helps eliminate the bacteria that cause meningitis from your nose and throat. It is important to use rifampin only for infections that are proven or strongly suspected to be caused by bacteria. This helps to prevent bacteria from becoming resistant to the medicine.
Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.
Rifampin works by stopping bacteria from growing and multiplying. It does this by blocking a key enzyme that the bacteria need to make proteins. This helps your body fight off the infection.
- • Upper respiratory infection (like a cold)
- • Urinary tract infection
- • Runny or stuffy nose
- • Diarrhea
- • Constipation
- • Heartburn
- • Upset stomach
- • Loss of appetite
- • Nausea
- • Vomiting
- Increased blood sugar 146
- Diabetic ketoacidosis 144
- Feeling sick to your stomach 102
- Fungal infection 92
- Weight loss 86
- Drug Interaction 970
- Drug Reaction With Eosinophilia And Systemic Symptoms 727
- Nausea 628
- Condition Aggravated 550
- Pyrexia 541
Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
Rifampin can cause liver problems. Tell your doctor right away if you have yellowing of the skin or eyes, dark urine, or stomach pain. Rifampin can also cause blood problems. Tell your doctor if you have unusual bleeding or bruising.
Glyxambi is not recommended during the second and third trimesters of pregnancy due to potential harm to the baby's kidneys. It is also not recommended while breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. Rifampin can make birth control pills less effective, so use other forms of birth control. Talk to your doctor if you are breastfeeding.
How to Read This empagliflozin/linagliptin vs rifampin Comparison
empagliflozin/linagliptin is classified in the SGLT2 / DPP-4 Combination drug class, while rifampin sits within the Rifamycin Antibiotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin/linagliptin has 570 submissions while rifampin has 3,416. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to rifampin makes your body process the diabetes medicine much faster than normal. this can prevent the medicine from staying in your system long enough to control your blood sugar.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for empagliflozin/linagliptin or rifampin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.